Biocardia Historical Income Statement
| BCDA Stock | USD 2.28 0.07 2.98% |
Historical analysis of Biocardia income statement accounts such as Interest Expense of 6.6 K, Selling General Administrative of 3.3 M or Total Revenue of 453.1 K can show how well Biocardia performed in making a profits. Evaluating Biocardia income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Biocardia's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Biocardia latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biocardia is a good buy for the upcoming year.
Biocardia |
About Biocardia Income Statement Analysis
Biocardia Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Biocardia shareholders. The income statement also shows Biocardia investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Biocardia Income Statement Chart
Add Fundamental
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Total Revenue
Total revenue comprises all receipts Biocardia generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Biocardia. It is also known as Biocardia overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Biocardia operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Biocardia is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from Biocardia's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Biocardia current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.At present, Biocardia's Cost Of Revenue is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 12.7 M, whereas Depreciation And Amortization is forecasted to decline to about 79.8 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 9K | 6K | 6.9K | 6.6K | Depreciation And Amortization | 640K | 82K | 84K | 79.8K |
Biocardia income statement Correlations
Click cells to compare fundamentals
Biocardia Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biocardia income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 196K | 566K | 640K | 82K | 84K | 79.8K | |
| Selling General Administrative | 6.0M | 5.9M | 5.1M | 4.4M | 4.4M | 3.3M | |
| Total Revenue | 710K | 145K | 1.0M | 1.4M | 477K | 453.2K | |
| Gross Profit | 352K | 141K | 375K | (10.5M) | (7.2M) | (6.9M) | |
| Other Operating Expenses | 14.9M | 15.7M | 13.6M | 13.3M | 12.1M | 6.4M | |
| Operating Income | (14.2M) | (15.5M) | (12.6M) | (11.9M) | (11.6M) | (11.1M) | |
| Ebit | (14.2M) | (15.0M) | (13.2M) | (11.9M) | (11.6M) | (11.1M) | |
| Ebitda | (14.0M) | (14.4M) | (12.6M) | (11.8M) | (11.6M) | (11.0M) | |
| Cost Of Revenue | 358K | 4K | 640K | 11.9M | 7.7M | 8.1M | |
| Total Operating Expenses | 14.6M | 15.7M | 13.6M | 13.3M | 12.1M | 12.7M | |
| Income Before Tax | (14.7M) | (15.0M) | (12.6M) | (11.9M) | (11.6M) | (11.0M) | |
| Total Other Income Expense Net | (496K) | 525K | 7K | (6K) | 73K | 76.7K | |
| Net Income | (14.8M) | (15.0M) | (12.6M) | (11.9M) | (11.6M) | (11.0M) | |
| Income Tax Expense | 110K | 1K | (2K) | 6K | 243.1K | 299.9K | |
| Research Development | 8.6M | 9.8M | 8.6M | 8.8M | 7.7M | 6.1M | |
| Net Income From Continuing Ops | (14.7M) | (15.0M) | (12.6M) | (11.9M) | (11.6M) | (12.1M) | |
| Net Income Applicable To Common Shares | (14.7M) | (15.0M) | (12.6M) | (11.9M) | (10.7M) | (11.3M) | |
| Interest Income | 118K | 87K | 21K | 9K | 8.1K | 7.7K | |
| Net Interest Income | 118K | (25K) | 18K | 9K | 10.4K | 10.9K | |
| Non Operating Income Net Other | 97K | 115K | (384K) | 528K | 607.2K | 637.6K | |
| Reconciled Depreciation | 111K | 68K | 60K | 82K | 84K | 65.3K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share 0.264 | Quarterly Revenue Growth (0.93) | Return On Assets (1.16) | Return On Equity (7.04) |
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.